India is known as the “Pharmacy of the World,” but now the focus is shifting towards innovation. Recently, experts highlighted the need for clinical data exclusivity to support MSME pharmaceutical companies in India.
Current Problem
At present, the company that first develops a new drug has to:
- Conduct clinical trials
- Spend a lot of money and time
- Get regulatory approvals
But after approval, other companies can launch the same drug by submitting basic data without doing full clinical trials.
This creates an unfair situation where:
- First company takes all the risk
- Other companies get easy entry
Impact on MSMEs
This problem mainly affects small and medium pharma companies (MSMEs):
- High investment but low return
- No protection for innovation
- Reduced interest in research
What is Clinical Data Exclusivity?
It means that the data created by the first company cannot be used by others for a limited time (usually 3–5 years).
Benefits:
- Protects innovation
- Helps recover costs
- Encourages more research
Global Practice
Countries like the US, Europe, and Japan already use this system to support pharma innovation.
Why Patents Are Not Enough
Patents do not always protect:
- New drug uses
- Improved formulas
- Drug delivery methods
So companies still face copying issues.
Conclusion
India needs clinical data exclusivity to:
- Support MSME innovators
- Encourage R&D
- Become a global pharma leader
Without it, companies may stop investing in innovation.
